Trade Olema Pharmaceuticals, Inc. - OLMA CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.05
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02221 %(-$0.44)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.00002 %(-$0.00)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02221 %
  (-$0.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00002 %
  (-$0.00)

Key Stats

• Prev. Close: 6.77
• Open: 6.73
• 1-Year Change: -37.1%
• Day's Range: 6.69 - 6.87

Trade Olema Pharmaceuticals, Inc. - OLMA

About Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It’s been ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Olema Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $24M to $71.1M. Higher net loss reflects Research and development increase from $11.7M to $41.8M (expense), Stock-based Compensation in R&D increase from $2M to $9.3M (expense), General and administrative - Balancing increase from $6.7M to $13.8M (expense).